AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33627609 — intervention group
Group type: COMPARATOR
Intervention: Control group (V-V ECMO without cytokine adsorption).
Number of subjects: 18
Study 33628143 — intervention group
Group type: EXPERIMENTAL
Intervention: Liwen procedure for myocardial biopsy
Number of subjects: 17
Study 33628355 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Behavioral Pain Scale (CBPS)
Number of subjects: 0
Study 33628355 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS)
Number of subjects: 0
Study 33628355 — intervention group
Group type: COMPARATOR
Intervention: Interrater reliability (CBPS scores)
Number of subjects: 0
Study 33628355 — intervention group
Group type: COMPARATOR
Intervention: Concurrent validity (preprocedure measurements)
Number of subjects: 0
Study 33628355 — intervention group
Group type: COMPARATOR
Intervention: Concurrent validity (postprocedure measurements)
Number of subjects: 0
Study 33628355 — intervention group
Group type: COMPARATOR
Intervention: Construct validity
Number of subjects: 0
Study 33628776 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training course for competency in arterial blood gas (ABG) sampling
Number of subjects: 56
Study 33628834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop (HCL) insulin delivery system with integrated continuous glucose monitoring (CGM)
Number of subjects: 6
Study 33629188 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) with warming and cooling sensations (hot tropical ginger, hot mango, cool red fruits, cool lemon, neutral)
Number of subjects: 50
Study 33629188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with taste alterations (TAs)
Number of subjects: 50
Study 33629188 — intervention group
Group type: COMPARATOR
Intervention: Patients without taste alterations (TAs)
Number of subjects: 50
Study 33629225 — intervention group
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 antigen test (12-min nasal swab)
Number of subjects: 512
Study 33629225 — intervention group
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 antigen test (nasopharyngeal swab)
Number of subjects: 512
Study 33629225 — intervention group
Group type: EXPERIMENTAL
Intervention: User error rate of the test system
Number of subjects: 512
Study 33629225 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of samples within 33 rt-PCR cycles
Number of subjects: 512
Study 33629404 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral anaesthesia
Number of subjects: 614
Study 33629410 — intervention group
Group type: EXPERIMENTAL
Intervention: Necklace-ECG (palm position)
Number of subjects: 145
Study 33629410 — intervention group
Group type: EXPERIMENTAL
Intervention: Necklace-ECG (chest position)
Number of subjects: 145
Study 33629410 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic AF detection algorithm (palm position)
Number of subjects: 145
Study 33629410 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic AF detection algorithm (chest position)
Number of subjects: 145
Study 33629819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months)
Number of subjects: 21
Study 33630047 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body fat (TBF)
Number of subjects: 90
Study 33630063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T treatment
Number of subjects: 0
Study 33630063 — intervention group
Group type: COMPARATOR
Intervention: Control antigens
Number of subjects: 0
Study 33630272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) therapy
Number of subjects: 1789
Study 33630272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Tocilizumab (TCZ) therapy
Number of subjects: 1789
Study 33630272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) therapy with known reasons for discontinuation
Number of subjects: 1789
Study 33630275 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg monotherapy
Number of subjects: 293
Study 33630503 — intervention group
Group type: EXPERIMENTAL
Intervention: Health service usability
Number of subjects: 66
Study 33630503 — intervention group
Group type: EXPERIMENTAL
Intervention: Trusting relationships with individual providers
Number of subjects: 66
Study 33630503 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of time demands and physical access challenges
Number of subjects: 66
Study 33630503 — intervention group
Group type: EXPERIMENTAL
Intervention: Configuration of connections to multiple health services
Number of subjects: 66
Study 33630532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Moms intervention (12-week program involving mindful physical activity using prenatal yoga)
Number of subjects: 0
Study 33630532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Moms intervention
Number of subjects: 0
Study 33630535 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial stress (in men)
Number of subjects: 0
Study 33630535 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial stress (in women)
Number of subjects: 0
Study 33630644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-related cues
Number of subjects: 0
Study 33630644 — intervention group
Group type: COMPARATOR
Intervention: Nondrug-related pleasant images
Number of subjects: 0
Study 33630747 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0
Study 33630747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting Time
Number of subjects: 0
Study 33630747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Habits (mMDS)
Number of subjects: 0
Study 33630747 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Consumption
Number of subjects: 0
Study 33630747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping Quality
Number of subjects: 0
Study 33630808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion (100-mL intravenous lipid emulsion)
Number of subjects: 58
Study 33630808 — intervention group
Group type: COMPARATOR
Intervention: HFLCD alone (control)
Number of subjects: 58
Study 33631079 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33631349 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated neuromodulation therapy
Number of subjects: 0
Study 33631774 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly prophylaxis with nonacog alfa 100 IU/kg (12 months)
Number of subjects: 25
Study 33631774 — intervention group
Group type: COMPARATOR
Intervention: On-demand nonacog alfa (6 months; dose at investigator's discretion)
Number of subjects: 25
Study 33631774 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly prophylaxis with nonacog alfa
Number of subjects: 25
Study 33631781 — intervention group
Group type: EXPERIMENTAL
Intervention: BN navigator assistance
Number of subjects: 100
Study 33631781 — intervention group
Group type: COMPARATOR
Intervention: No unmet BNs
Number of subjects: 100
Study 33631781 — intervention group
Group type: COMPARATOR
Intervention: Pre-study adherence rates
Number of subjects: 100
Study 33632138 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 40
Study 33632138 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 40
Study 33632138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound quadriceps
Number of subjects: 40
Study 33632138 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Analysis (BIA)
Number of subjects: 40
Study 33632149 — intervention group
Group type: EXPERIMENTAL
Intervention: WMH pathology
Number of subjects: 231
Study 33632149 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA pathology
Number of subjects: 231
Study 33632149 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemispheric stroke
Number of subjects: 231
Study 33632149 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke lesion volume
Number of subjects: 231
Study 33632155 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cell infusion
Number of subjects: 13
Study 33632171 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive participants
Number of subjects: 467
Study 33632171 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants with SARS-CoV-2 antibodies
Number of subjects: 467
Study 33632171 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants with SARS-CoV-2 antibodies
Number of subjects: 467
Study 33632175 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing four or more ACEs
Number of subjects: 889
Study 33632175 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing community violence or family distress
Number of subjects: 889
Study 33632205 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention
Number of subjects: 57
Study 33632262 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-FES hand therapy system
Number of subjects: 8
Study 33632271 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional questionnaire for ICU survivors
Number of subjects: 395
Study 33632271 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ICU-treated)
Number of subjects: 395
Study 33632313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-guided activity (PGA)
Number of subjects: 15
Study 33632313 — intervention group
Group type: COMPARATOR
Intervention: Pain-free activity (PFA)
Number of subjects: 15
Study 33632313 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA and PFA groups
Number of subjects: 15
Study 33632330 — intervention group
Group type: EXPERIMENTAL
Intervention: HENRY intervention (Health, Exercise, Nutrition for the Really Young)
Number of subjects: 117
Study 33632330 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 117
Study 33632492 — intervention group
Group type: EXPERIMENTAL
Intervention: Different plaque imaging techniques
Number of subjects: 0
Study 33632492 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33632707 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity measures (BMI, WC, HC, WHR)
Number of subjects: 2493
Study 33632707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia measures (insulin, HOMA-IR, HOMA-%β)
Number of subjects: 2493
Study 33632753 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated assay measuring serum concentrations of GFAP and UCH-L1
Number of subjects: 1760
Study 33632755 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health solutions
Number of subjects: 0
Study 33632769 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 42
Study 33632769 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 min walk test
Number of subjects: 42
Study 33632769 — intervention group
Group type: EXPERIMENTAL
Intervention: log to base 10 N-terminal pro-brain natriuretic peptide
Number of subjects: 42
Study 33632775 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib (TAK-788)
Number of subjects: 0
Study 33632775 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33632799 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 11243
Study 33632799 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma+COPD
Number of subjects: 11243
Study 33632799 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 11243
Study 33632799 — intervention group
Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 11243
Study 33632874 — intervention group
Group type: EXPERIMENTAL
Intervention: NLG207 (Formerly CRLX101) in combination with Enzalutamide
Number of subjects: 0
Study 33632874 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide alone
Number of subjects: 0
Study 33633029 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgical interventions
Number of subjects: 34
Study 33633029 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 34
Study 33633029 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 34
Study 33633029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure germinoma tumors (PG)
Number of subjects: 34
Study 33633029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongerminomatous germ cell tumors (NGGCT)
Number of subjects: 34
Study 33633029 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related toxicity
Number of subjects: 34
Study 33633029 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 34
Study 33633114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentivirus-mediated gene therapy
Number of subjects: 5
Study 33633187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 32
Study 33633187 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 32
Study 33633187 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid peroxide (PerOx)
Number of subjects: 32
Study 33633187 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thiols
Number of subjects: 32
Study 33633187 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plasma antioxidant capacity (TAC)
Number of subjects: 32
Study 33633187 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 32
Study 33633187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidised LDL (oxLDL)
Number of subjects: 32
Study 33633498 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention over 16 weeks
Number of subjects: 0
Study 33633498 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 0
Study 33633648 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game platform for Home-Based Telerehabilitation
Number of subjects: 22
Study 33633648 — intervention group
Group type: COMPARATOR
Intervention: Typically developing individuals (control group)
Number of subjects: 22
Study 33633656 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 0
Study 33633656 — intervention group
Group type: EXPERIMENTAL
Intervention: Homotaurine
Number of subjects: 0
Study 33633656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 0
Study 33633977 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage direct-to-implant technique using acellular dermal matrix (ADM)
Number of subjects: 44
Study 33633977 — intervention group
Group type: COMPARATOR
Intervention: Two-stage expander-to-implant technique
Number of subjects: 44
Study 33633977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 33634616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% HA gel
Number of subjects: 61
Study 33634616 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (no gel)
Number of subjects: 61
Study 33634616 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (excipient-based gel)
Number of subjects: 61
Study 33634729 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19
Number of subjects: 0
Study 33634729 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 33634729 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 vs SoC
Number of subjects: 0
Study 33634772 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Healthy Lifestyle Score (HLS)
Number of subjects: 2981
Study 33635141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast 100 mg/day
Number of subjects: 239
Study 33635141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 33635276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile sleep hygiene advice (n=30)
Number of subjects: 110
Study 33635276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile sleep hygiene advice and sleep and alcohol diary self-monitoring (n=30)
Number of subjects: 110
Study 33635276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile sleep hygiene advice, sleep and alcohol diary self-monitoring, and sleep and alcohol data feedback (n=60)
Number of subjects: 110
Study 33635333 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus and MMF following PTCy
Number of subjects: 32
Study 33635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33636137 — intervention group
Group type: EXPERIMENTAL
Intervention: High minority enrollment
Number of subjects: 4184
Study 33636137 — intervention group
Group type: EXPERIMENTAL
Intervention: High female enrollment
Number of subjects: 4184
Study 33636389 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light chain (NfL) measurements
Number of subjects: 62
Study 33636454 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Azacitidine (15, 30, and 45 mg/m daily on days 1-5 and 15-19 of 28-day cycles)
Number of subjects: 8
Study 33636454 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Azacitidine (higher doses)
Number of subjects: 8
Study 33636454 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Azacitidine (pre- and post-treatment bronchoscopy)
Number of subjects: 8
Study 33636843 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured GFR
Number of subjects: 96
Study 33636851 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloSure® (targeted next-generation sequencing-based approach)
Number of subjects: 93
Study 33637087 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin use
Number of subjects: 510
Study 33637087 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin initiation
Number of subjects: 510
Study 33637216 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) intervention, 10 sessions lasting 50 minutes each over 5 weeks
Number of subjects: 33
Study 33638035 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM447 250 mg QD
Number of subjects: 13
Study 33638035 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM447 300 mg QD
Number of subjects: 13
Study 33638057 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS)
Number of subjects: 60
Study 33638057 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 60
Study 33638057 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS and CT correlation
Number of subjects: 60
Study 33638057 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to pleura
Number of subjects: 60
Study 33638057 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS findings
Number of subjects: 60
Study 33638057 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to pleura correlation
Number of subjects: 60
Study 33638113 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-TTR-L
Number of subjects: 140
Study 33638113 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study 33638249 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative assessment and provision of perioperative support
Number of subjects: 120
Study 33638249 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews
Number of subjects: 120
Study 33638263 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (escitalopram or duloxetine) for 8 weeks
Number of subjects: 41
Study 33638263 — intervention group
Group type: COMPARATOR
Intervention: Treatment-naïve patients
Number of subjects: 41
Study 33638811 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole exposure
Number of subjects: 32
Study 33638863 — intervention group
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS 300 μg once daily for 29 days
Number of subjects: 22
Study 33638863 — intervention group
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Number of subjects: 22
Study 33639190 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-pelvis intensity-modulated radiotherapy (WPRT)
Number of subjects: 415
Study 33639190 — intervention group
Group type: EXPERIMENTAL
Intervention: DVH (best cut-off: V46Gy ≥80 cc)
Number of subjects: 415
Study 33639190 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained bowel loops (V46 < 80 cc)
Number of subjects: 415
Study 33639216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 139
Study 33639518 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training with music therapy (2 sessions per week for 3 months)
Number of subjects: 66
Study 33639518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 33639779 — intervention group
Group type: EXPERIMENTAL
Intervention: Total squared changes of Mel-Frequency Cepstral Coefficients (TSC_MFCC)
Number of subjects: 0
Study 33639779 — intervention group
Group type: EXPERIMENTAL
Intervention: Durational measures
Number of subjects: 0
Study 33639900 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells (UC-MSCs) injected intravenously at a dose of 1 × 10^6 cells/kg
Number of subjects: 18
Study 33639900 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (IST)
Number of subjects: 18
Study 33639900 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells (UC-MSCs) with IST
Number of subjects: 18
Study 33639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Midkine inhibition via adeno-associated virus (AAV) targeting; specific dosage and duration not mentioned.
Number of subjects: 0
Study 33639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Midkine levels in plasma and lung; specific dosage and duration not mentioned.
Number of subjects: 0
Study 33639987 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro study using inhibitors targeting candidate receptors of midkine; specific dosage and duration not mentioned.
Number of subjects: 0
Study 33639990 — intervention group
Group type: EXPERIMENTAL
Intervention: Miransertib treatment for a median duration of 22 months (range 22-28).
Number of subjects: 2
Study 33640028 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators identified include 'recognizing and addressing' by close others, 'waiting times and availability', 'recommendations and referrals' by health care professionals, and 'positive role models for treatment'.
Number of subjects: 22
Study 33640028 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers identified include factors within the patient, social environment, health care system, and society.
Number of subjects: 22
Study 33640346 — intervention group
Group type: EXPERIMENTAL
Intervention: His-optimized cardiac resynchronization therapy (HOT-CRT)
Number of subjects: 19